


Compare country-specific data for products of interest in the Analysis table

This guide explains how to customize the country-specific data in an Analysis table so you can compare local information on products of interest - either competitor products or potential candidates for your portfolio.

The Analysis table in the Product Selector Tool helps you evaluate your specific market by answering questions such as: When is the first product patent expiring in my country? Who is marketing this product*? What is the local brand name*? And more.

Example: Identify the first product patent expiry date, names of marketers and local brand names for tyrosine kinase inhibitors such as *ibrutinib*, *gefitinib* and *imatinib mesylate* in Brazil.


1. Login to [Cortellis Product Intelligence](#).
2. Go to the **Product Selector Tool** and scroll down.




3. **Enter the API names** of interest, select from the suggestions and click 'Search'.




- The Analysis table offers a drop-down menu at the top to **select the country** of interest. Type and select 'Brazil'.



- Click '**Customize columns**' to hide, show and reorder columns in your Analysis table.



6. Display the first product patent expiry date, names of marketers and local brand name for the products of interest. **Sorting options at the top** allow you to rank results by sales trend, for example.



API NAME ↑	LOCAL BRAND NAME BRAZIL	LOCAL MARKETERS BRAZIL	NO. OF LOCAL MARKETERS BRAZIL	1ST PRODUCT PATENT ESTIMATED EXPIRY DATE BRAZIL
<input type="checkbox"/> Imatinib mesylate	GLIMATIN GLIVEC ...	Novartis AG Sun Pharmaceutical Ind... ...	7	03-Apr-2012
<input type="checkbox"/> Gefitinib	GEFIB GEFITINIBE MG ...	Cipla Ltd Natco Pharma Ltd ...	4	23-Apr-2016
<input type="checkbox"/> Ibrutinib	IMBRUVICA	Johnson & Johnson	1	28-Dec-2026

As of Aug 2023:

- *Imatinib mesylate* aka *Glivec* and *Glimatin* had at least 7 launches in Brazil by Novartis, Sun Pharma and other companies.
- *Gefitinib* aka *Gefib* and *Gefitinibe* had 4 including Cipla and Natco.
- *Ibrutinib* aka *Impruvica* -developed by J&J- is still protected by its first product patent and doesn't seem to have any generic launches.

* Users with access to Cortellis Product Global and Premium can also display and export sales volume, sales trends, indications, highest phase reached, brand names, number of marketers and names. In addition, users with access to Cortellis Product Premium are able to display and export API consumption and trends.

To find out what's included in your subscription, contact your Clarivate account manager or **LS Product Support**.